[Neurochemical early and differential diagnostics for Alzheimer's disease].
Current medication procedures for Alzheimer's dementia (AD) such as inhibitors of acetyl cholinesterase or Memantine and future therapeutic approaches demand improved early diagnostics. However, the differentiation between early cognitive impairments due to primary progressive demential conditions and cognitive deficits in geriatric or depressive people is a great clinical challenge. The detection of biochemical markers such as beta-amyloid peptide and tau proteins in the cerebrospinal fluid can lead to improved diagnostics of the early stages and premonitory symptoms of AD. As a result, future preventive drug treatment strategies can be employed early and selectively.
Wiltfang
J
J
Klinik mit Poliklinik für Psychiatrie und Psychotherapie Friedrich-Alexander-Universität Erlangen-Nürnberg. Jens.Wiltfang@psych.imed.uni-erlangen.de
Lewczuk
P
P
Maler
M
M
Bleich
St
S
Smirnov
A
A
Kornhuber
J
J
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000175:diagnosis* / Q000523:psychology; D042241:Early Diagnosis; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011379:Prognosis; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; D016875:tau Proteins